Fairvalue-Calculator Fairvalue-Calculator
EN DE

Evolus, Inc (EOLS) Fair Value & Analysis

Healthcare · US · Market cap $437M

Price$6.59
Fair Value$15.79
Upside+139.6%
Quality95/100
Evidence: Low Range $11.85 – $19.74

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Evolus, Inc (EOLS) currently trades at $6.59, while our model-based Fair Value estimate is $15.79 — implying the stock looks roughly 139.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Evolus, Inc (EOLS) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $15.79 versus a price of $6.59 — about +140% (undervalued). Model-based estimate, not financial advice.
What is the fair value of EOLS?
Our 21-model fair value for Evolus, Inc is $15.79 (as of Jun 23, 2026), built from audited fundamentals. The current price is $6.59.
What is the quality score of EOLS?
Evolus, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.